New tuberculosis vaccine: resuming recruitment

A new version of the protocol has been adopted, according to which, in August 2023, the recruitment of patients who have undergone tuberculosis will begin to participate in the study of the GamTBVac vaccine for the prevention of relapse. We invite participants to the preliminary selection. Write to us 8 (993) 202 7840

Our partners

Protagonist
Gilead
Mithra
PRA Health Sciences
Pfizer
Rusmo-AG
Sanofi
Abbvie
Icon
Astra Zeneca
Gedeon Richter
Cromos Pharma
PPD
X7 Research
Synteract
IQVIA
Biorasi | Built for Faster Clinical Trials
PSI
ALK
Galecto
SRG
Clinipas
Astellas
Janssen
JonsonAndJonson
OCT
Celgen
Bristol-Myers Squibb Company
Biogen